“It's the balance of the aggressive immune reaction against the inhibitory molecules that can prevent that immune reaction that is the holy grail of trying to find effective treatments.” —Steven
Rosenbergpeterattiamd.com/stevenrose...
“It's the balance of the aggressive immune reaction against the inhibitory molecules that can prevent that immune reaction that is the holy grail of trying to find effective treatments.” —Steven
Rosenbergpeterattiamd.com/stevenrose...
Thanks for that link. I used to subscribe to petter attia “the drive” this is s great interview. What Dr Rosenberg said on minute 35:30 “my view of the dirty little secret of oncology if the cancer has spread from its local site and cannot be surgically removed then the death rate is 100%.
Except for 4 cancers, but this interview was in Sep 2021, and before the miraculous drug dostarlimab in colon cancer patients.
Chilling but im not giving into that line of thinking
Center for Cancer Research
National Cancer Institute
Building 10 - Hatfield CRC, Room 3-3940
Bethesda, MD 20892-1201
240-858-3080
SAR@nih.gov
CHIEF
Surgery Branch
SENIOR INVESTIGATOR
HEAD, TUMOR IMMUNOLOGY SECTION
RESEARCH SUMMARY
Dr. Rosenberg pioneered the development of effective immunotherapies and gene therapies for patients with advanced cancers. His studies of the adoptive transfer of genetically modified lymphocytes have resulted in the regression of metastatic cancer in patients with melanoma, sarcomas and lymphomas. His current research is aimed at defining the host immune response of patients to their cancers. These studies emphasize the ability of human lymphocytes to recognize unique cancer antigens and the identification of anti-tumor T cell receptors that can be exploited to develop new cell transfer immunotherapies for the treatment of cancer patients. As Chief, Dr. Rosenberg also oversees the Branch’s extensive clinical program aimed at translating scientific advances into effective immunotherapies for patients with cancer.
Good Luck, Good Health and Good Humor.
j-o-h-n Tuesday 07/12/2022 6:42 PM DST